Full Breakdown
Viagra’s Potential Role in Slowing Cancer Spread: Lab Findings Meet Real-World Data
8/5/2026, 7:57:59 PM
Core Study Findings
Researchers at Israel’s Weizmann Institute, Clalit Health Services and the U.S. National Cancer Institute reported that sildenafil—the active ingredient in Viagra—interferes with cancer cells’ ability to obtain cholesterol, a resource for metastasis. Mouse models and human-derived cancer cell cultures showed reduced metastatic activity when sildenafil was applied. An epidemiological analysis of roughly five million Clalit members found that male patients who used sildenafil before a cancer diagnosis had better overall survival, especially when they also used statins. The study, published in *Cancer Research* (July), combined mechanistic lab data with a retrospective cohort of about 40 000 male cancer patients.
Background & Context
Viagra, approved for erectile dysfunction in 1998, inhibits phosphodiesterase type 5 (PDE5), raising cyclic GMP (cGMP) levels and relaxing blood vessels. The new work identified that elevated cGMP binds to a cholesterol-transport protein, limiting intracellular cholesterol. Because metastatic cells rely on cholesterol to detach and invade other organs, restricting this supply appears to hinder spread. The researchers also noted a synergistic effect with statins, which lower cholesterol production.
Key Researchers
- Dr. Samah Hayek, MD – Senior epidemiologist, Clalit Research Institute.
- Dr. Yarden Ariav, PhD – Lead investigator, Weizmann Institute.
- Prof. Ayelet Erez, MD, PhD – Senior researcher, Weizmann medical school.
Data & Statistics
- Cohort size: ~5 million Clalit members; ~40 000 male cancer patients examined.
- Time span: Over 20 years of anonymized health records.
- Survival association: Prior sildenafil use linked to higher overall survival, strongest among statin users.
- Laboratory models: Fewer metastases in mice and human cell cultures treated with sildenafil, with greater reduction when combined with statins.
Official Statements & Responses
Researchers emphasized that the findings are preliminary. Dr. Hayek said the study “bridges two worlds,” linking a laboratory mechanism with real-world outcomes, but noted the analysis only considered medication use before cancer diagnosis. Prof. Erez highlighted the need for a clinical trial, proposing to test sildenafil in women with triple-negative breast cancer. Dr. Wolf described the work as “translational science” moving from mouse modeling to human data.
Conflicting Reports & Gaps
- Gender limitation: Analysis focused on men because sildenafil is primarily prescribed to males; effects in women remain unknown.
- Causality vs. association: The data show correlation, not proof of benefit; factors such as age, cancer type, stage, health status and other treatments could influence outcomes.
- Cancer-type specificity: Overall survival was assessed across a broad cohort without isolating individual tumor types.
What’s Next
Prof. Erez announced plans for a clinical trial evaluating sildenafil in women with triple-negative breast cancer to test whether the metabolic mechanism observed preclinically translates into therapeutic benefit.
Verbatim Quotes
- “This is an interesting study, and it was well-designed,” — S. Adam Ramin
- “Our retrospective analysis included mainly men because sildenafil is predominantly prescribed to men,” — Samah Hayek
- “These results are preclinical — meaning the data were derived from cell lines or mice,” — Mike Lattanzi
